EFFECTIVE HALF-LIFE, EXCRETION AND RADIATION EXPOSURE OF 177LU-PSMA

PARLAK Y., Mutevellzade G., Sezgln C., Goksoy D., Gumuser G., Saylt E.

Radiation Protection Dosimetry, vol.199, no.10, pp.1090-1095, 2023 (SCI-Expanded, Scopus) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 199 Issue: 10
  • Publication Date: 2023
  • Doi Number: 10.1093/rpd/ncad141
  • Journal Name: Radiation Protection Dosimetry
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Applied Science & Technology Source, Biotechnology Research Abstracts, CAB Abstracts, Chimica, Environment Index, Index Islamicus, INSPEC, Pollution Abstracts, Veterinary Science Database
  • Page Numbers: pp.1090-1095
  • Manisa Celal Bayar University Affiliated: Yes

Abstract

The study aims to evaluate the radiation safety conditions by detecting the patient's urine excretion rate, calculating the effective half-life, and determining the retention of 177Lu-PSMA in the body. Urine samples of patients were collected for 24 hours (6, 12, 18, and 24 hours) following the infusion, excretion rate and retention of 177Lu-PSMA in the body of patients were calculated. The measurements of dose rate were performed. Effective half-life calculated from dose rate measurements was found as 18.5 ± 11 h within the first 24 h and 48.1 ± 22.8 h between 24 and 72 h. Excreted activity in urine was found as 33.8 ± 20.7, 40.4 ± 20.3, 46.1 ± 22.4, and 53.3 ± 21.5% of total doses at 6, 12, 18, and 24 h after administration, respectively. External dose rates for 4 h and 24 h were 24.51 μSv/h, 16.14 μSv/h, respectively. Our results showed that 177Lu-PSMA treatment was suitable for outpatient treatment in terms of radiation safety.